<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82284">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01886248</url>
  </required_header>
  <id_info>
    <org_study_id>Antithrombin-III</org_study_id>
    <nct_id>NCT01886248</nct_id>
  </id_info>
  <brief_title>Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of AT-III treatment in patients with hepatic veno-occlusive
      diseases following hematopoietic stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AT-III level before 5th dose of AT-III</measure>
    <time_frame>up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AT-III level before 9th dose</measure>
    <time_frame>up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hepatic Veno-Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>Antithrombin-III Human 500IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
Units required (IU)/kg = 50 + [(desired-baseline AT-III level) x weight (kg) / 1.4]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU</intervention_name>
    <arm_group_label>Antithrombin-III Human 500IU</arm_group_label>
    <other_name>Antithrombin-III Human 500IU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with hepatic veno-occlusive disease after hematopoietic stem cell
             transplantation. The following criteria will be used.

               1. Two of the following

                    -  Serum total bilirubin &gt; 2.0 mg/dL

                    -  Hepatomegaly or right upper quadrant pain of liver origin

                    -  Unexplained weight gain of&gt;2% over baseline because of fluid accumulation

               2. Patients with pathologic diagnosis.

          2. Patients with informed consent

        Exclusion Criteria:

          1. Pregnant or nursing women.

          2. Malignant or nonmalignant illness that is uncontrolled or whose control may be
             jeopardized by complications of study therapy.

          3. Psychiatric disorder that would preclude compliance.

          4. Patients who, in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study.

          5. History of anaphylactic reaction to the study drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, MD, Ph.D</last_name>
    <phone>82 2 2072 3304</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Won Lee, MD</last_name>
    <phone>82 2 2072 4192</phone>
    <email>agnesjw@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Chongno-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, M.D, Ph.D</last_name>
      <phone>82 2 2072 3304</phone>
      <email>kanghj@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 17, 2013</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic veno-occlusive disease after hematopoietic stem cell transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
    <mesh_term>Budd-Chiari Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
    <mesh_term>Antithrombin Proteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
